oxybutynin has been researched along with Parkinson Disease, Secondary in 3 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We previously reported the induction of catalepsy by amiodarone, aprindine and procaine, which possess a diethylaminomethyl moiety and demonstrated selective blockade of dopamine D2 receptors by these drugs in mice." | 1.31 | Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice. ( Hattori, F; Inoue, N; Matsui, A; Matsuo, H; Nasu, R; Ohtani, H; Sawada, Y; Takanaga, H, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsuo, H | 1 |
| Matsui, A | 1 |
| Nasu, R | 1 |
| Takanaga, H | 1 |
| Inoue, N | 1 |
| Hattori, F | 1 |
| Ohtani, H | 1 |
| Sawada, Y | 1 |
| Zarola, F | 1 |
| Marchitto, N | 1 |
| Sindona, F | 1 |
| Pannozzi, A | 1 |
| Dalmaso, SG | 1 |
| Anticoli, S | 1 |
| Raimondi, G | 1 |
3 other studies available for oxybutynin and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice.
Topics: Animals; Antitussive Agents; Benzilates; Catalepsy; Cholinergic Antagonists; Cyclopentanes; Male; Ma | 2000 |
Vascular Parkinsonism sensitive to Rotigotine therapy is found in aged patients: a clinical case description.
Topics: Aged, 80 and over; Cerebral Infarction; Dopamine Agonists; Female; Humans; Magnetic Resonance Imagin | 2018 |
Safety and efficacy of Rotigotine in hospedalized patients with Vascular Parkinsonism aged 75 and older: effects on movement, praxis capacities, time-space orientation, quality of life and adherence to medical therapy.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Brain Ischemia; Cognition; Dopamine Agonists; Fe | 2019 |